Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Aug;165(2):609-16.
doi: 10.1016/S0002-9440(10)63325-1.

Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease

Affiliations

Loss of LFA-1, but not Mac-1, protects MRL/MpJ-Fas(lpr) mice from autoimmune disease

Christopher G Kevil et al. Am J Pathol. 2004 Aug.

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune complex-mediated tissue injury. Many different adhesion molecules are thought to participate in the development of SLE; however, few studies have directly examined the contributions of these proteins. Here we demonstrate that LFA-1 plays an essential role in the development of lupus in MRL/MpJ-Fas(lpr) mice. Mice deficient in LFA-1, but not Mac-1, showed significantly increased survival, decreased anti-DNA autoantibody formation, and reduced glomerulonephritis. The phenotype of the LFA-1-deficient mice was similar to that observed in beta(2) integrin-deficient (CD18-null) MRL/MpJ-Fas(lpr) mice, suggesting a lack of redundancy among the beta(2) integrin family members and other adhesion molecules. These studies identify LFA-1 as a key contributor in the pathogenesis of autoimmune disease in this model, and further suggest that therapeutic strategies targeting this adhesion molecule may be beneficial for the treatment of SLE.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phenotypic characteristics of mutant MRL/MpJ-Faslpr mice. a: Twenty-week-old control MRL/MpJ-Faslpr (male), CD18−/− (male and female), CD11b−/− (male and female), or CD11a−/− (male and female) are shown from left to right. b: Kaplan-Meier survival analysis between control MRL/MpJ-Faslpr (▪, n = 25), CD11a−/− (▴, n = 30), and CD11b−/− (▾, n = 24) mice. c: BUN measurements from five male and five female, 20-week-old mice. *, P < 0.05.
Figure 2
Figure 2
Glomerular ultrastructure. A: Control MRL/MpJ-Faslpr representative glomerulus from a 20-week-old mouse. Extensive electron-dense deposits (d) within the markedly expanded mesangium of the glomerulus were observed (b = basement membrane). B: CD18−/−, 20-week-old mouse. Marked reduction in glomerular deposits with distinct, nonconfluent, small electron-dense deposits within the basement membrane. C: CD11a−/−, 20-week-old mouse. Occasional linear electron-dense deposits were noted in the paramesangial areas abutting the basement membranes and within the glomerular basement membranes. D: CD11b−/−, 20-week-old mouse. Abundant confluent electron-dense deposits were readily seen within the mesangial regions (arrows). Epimembranous and membranous deposits (arrowheads) were also present within glomerular basement membranes. Original magnifications, ×5000.
Figure 3
Figure 3
Renal lesion scores for control MRL/MpJ-Faslpr mice (n = 6), CD18−/− mice (n = 3), CD11a−/− mice (n = 6), and CD11b−/− mice (n = 4). Means ± SD. Bars designated with different letter codes are significantly different (P < 0.05).
Figure 4
Figure 4
Glomerular histopathology. A: Control MRL/MpJ-Faslpr mouse at death (23 weeks old). Severe glomerulitis with neutrophil accumulation, necrosis, sclerosis, crescent formation with synechia, and capsular fibrosis. B: CD18−/− mouse at death (34 weeks old). Mild neutrophil accumulation. C: CD11a−/− mouse at death (43 weeks old). Mild neutrophil accumulation. D: CD11b−/− mouse at death (24 weeks old). Severe glomerulitis similar to that in A. H&E. Original magnifications, ×20.
Figure 5
Figure 5
Serum IgG anti-double-stranded and single-stranded DNA antibodies. a: IgG anti-double-stranded DNA antibody titers between control MRL/MpJ-Faslpr (▪, n = 25) and CD18−/− (•, n = 25) mice. b: IgG anti-double-stranded DNA antibody titers between control MRL/MpJ-Faslpr (▪, n = 25) and CD11a−/− (▴, n = 25) mice. c: IgG anti-single-stranded DNA antibody titers between control MRL/MpJ-Faslpr (▪, n = 25) and CD18−/− (•, n = 25) mice. d: IgG anti-single-stranded DNA antibody titers between control MRL/MpJ-Faslpr (▪, n = 25) and CD11a−/− (▴, n = 25) mice. *, P < 0.01.
Figure 6
Figure 6
Total serum immunoglobulin levels. a: Total serum IgG concentrations between control MRL/MpJ-Faslpr (▪, n = 25) and CD18−/− (•, n = 25) mice. b: Total serum IgM concentrations between control MRL/MpJ-Faslpr (▪, n = 25) and CD18−/− (•, n = 25) mice. c: Total serum IgG concentrations between control MRL/MpJ-Faslpr (▪, n = 25) and CD11a−/− (▴, n = 25) mice. d: Total serum IgM concentrations between control MRL/MpJ-Faslpr (▪, n = 25) and CD11a−/− (▴, n = 25) mice. *, P < 0.01.

Similar articles

Cited by

References

    1. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56:481–490. - PMC - PubMed
    1. Mageed RA, Prud’homme GJ. Immunopathology and the gene therapy of lupus. Gene Ther. 2003;10:861–874. - PubMed
    1. Pollard KM, Hultman P, Kono DH. Using single-gene deletions to identify checkpoints in the progression of systemic autoimmunity. Ann NY Acad Sci. 2003;987:236–239. - PubMed
    1. Cravens PD, Lipsky PE. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol. 2002;80:497–505. - PubMed
    1. Sturfelt G. The complement system in systemic lupus erythematosus. Scand J Rheumatol. 2002;31:129–132. - PubMed

Publication types

MeSH terms